These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 31078775)

  • 1. Immune Cell Infiltration May Be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer.
    Muppa P; Parrilha Terra SBS; Sharma A; Mansfield AS; Aubry MC; Bhinge K; Asiedu MK; de Andrade M; Janaki N; Murphy SJ; Nasir A; Van Keulen V; Vasmatzis G; Wigle DA; Yang P; Yi ES; Peikert T; Kosari F
    J Thorac Oncol; 2019 Jul; 14(7):1286-1295. PubMed ID: 31078775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy.
    Jiang Y; Xie J; Cheng Q; Cai Z; Xu K; Lu W; Wang F; Wu X; Song Y; Lv T; Zhan P
    Int Immunopharmacol; 2024 Nov; 141():112901. PubMed ID: 39151386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
    Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes.
    Iams WT; Shiuan E; Meador CB; Roth M; Bordeaux J; Vaupel C; Boyd KL; Summitt IB; Wang LL; Schneider JT; Warner JL; Zhao Z; Lovly CM
    J Thorac Oncol; 2019 Nov; 14(11):1970-1981. PubMed ID: 31201935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution.
    Dora D; Rivard C; Yu H; Bunn P; Suda K; Ren S; Lueke Pickard S; Laszlo V; Harko T; Megyesfalvi Z; Moldvay J; Hirsch FR; Dome B; Lohinai Z
    Mol Oncol; 2020 Sep; 14(9):1947-1965. PubMed ID: 32506804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
    Berghoff AS; Ricken G; Wilhelm D; Rajky O; Widhalm G; Dieckmann K; Birner P; Bartsch R; Preusser M
    J Neurooncol; 2016 Oct; 130(1):19-29. PubMed ID: 27436101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer.
    Chen P; Zhao L; Wang H; Zhang L; Zhang W; Zhu J; Yu J; Zhao S; Li W; Sun C; Wu C; He Y; Zhou C
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes.
    Bonanno L; Pavan A; Dieci MV; Di Liso E; Schiavon M; Comacchio G; Attili I; Pasello G; Calabrese F; Rea F; Favaretto A; Rugge M; Guarneri V; Fassan M; Conte PF
    Eur J Cancer; 2018 Sep; 101():191-200. PubMed ID: 30077124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
    Carvajal-Hausdorf D; Altan M; Velcheti V; Gettinger SN; Herbst RS; Rimm DL; Schalper KA
    J Immunother Cancer; 2019 Mar; 7(1):65. PubMed ID: 30850021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galectin-9-based immune risk score model helps to predict relapse in stage I-III small cell lung cancer.
    Chen P; Zhang L; Zhang W; Sun C; Wu C; He Y; Zhou C
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical Resection of SCLC: Prognostic Factors and the Tumor Microenvironment.
    Zhao X; Kallakury B; Chahine JJ; Hartmann D; Zhang Y; Chen Y; Zhang H; Zhang B; Wang C; Giaccone G
    J Thorac Oncol; 2019 May; 14(5):914-923. PubMed ID: 30735815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer.
    Zhang Z; Wu P; Zhang C; Luo Y; Zhang G; Zeng Q; Wang L; Yang Z; Sun N; He J
    Front Immunol; 2021; 12():745769. PubMed ID: 34867972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.
    Chang YL; Yang CY; Huang YL; Wu CT; Yang PC
    Oncotarget; 2017 Mar; 8(11):18021-18030. PubMed ID: 28152514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer.
    Cai L; Liu H; Huang F; Fujimoto J; Girard L; Chen J; Li Y; Zhang YA; Deb D; Stastny V; Pozo K; Kuo CS; Jia G; Yang C; Zou W; Alomar A; Huffman K; Papari-Zareei M; Yang L; Drapkin B; Akbay EA; Shames DS; Wistuba II; Wang T; Johnson JE; Xiao G; DeBerardinis RJ; Minna JD; Xie Y; Gazdar AF
    Commun Biol; 2021 Mar; 4(1):314. PubMed ID: 33750914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immune Characteristics of Small Cell Lung Cancer].
    Zhu Y; Wu S
    Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):889-896. PubMed ID: 33070515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung.
    Kim HS; Lee JH; Nam SJ; Ock CY; Moon JW; Yoo CW; Lee GK; Han JY
    J Thorac Oncol; 2018 May; 13(5):636-648. PubMed ID: 29378266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Immune Infiltration and Prognostic Biomarkers in Small Cell Lung Cancer Based on Bioinformatic Methods from 3 Studies.
    Cao J; Yu C
    Comb Chem High Throughput Screen; 2023; 26(3):507-516. PubMed ID: 35400336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological characteristics of thyroid transcription factor 1-negative small cell lung cancers.
    Iida Y; Masuda S; Nakanishi Y; Shimizu T; Nishimaki H; Takahashi M; Hikichi M; Maruoka S; Gon Y; Takahashi N; Hashimoto S
    Hum Pathol; 2018 Sep; 79():127-134. PubMed ID: 29787820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Bioinformatics Analysis Identifies Tumor Microenvironment and Immune-related Genes in Small Cell Lung Cancer.
    Song Y; Sun Y; Sun T; Tang R
    Comb Chem High Throughput Screen; 2020; 23(5):381-391. PubMed ID: 32264809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.
    Yu H; Batenchuk C; Badzio A; Boyle TA; Czapiewski P; Chan DC; Lu X; Gao D; Ellison K; Kowalewski AA; Rivard CJ; Dziadziuszko R; Zhou C; Hussein M; Richards D; Wilks S; Monte M; Edenfield W; Goldschmidt J; Page R; Ulrich B; Waterhouse D; Close S; Jassem J; Kulig K; Hirsch FR
    J Thorac Oncol; 2017 Jan; 12(1):110-120. PubMed ID: 27639678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.